SCHEMBL5473232

SCHEMBL5473232

Cc1ccc(-c2ccnc(NC(=O)c3ccccc3)n2)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 1/20 0.63
CYP1A2 P05177 1/20 0.62
CYP3A4 P08684 1/20 0.62
CYP2C19 P33261 1/20 0.62
JAK2 O60674 2/20 0.57
ADORA1 P30542 2/20 0.57
CAMK2D Q13557 2/20 0.56
ABL1 P00519 4/20 0.55
PDGFRB P09619 4/20 0.55
BCR P11274 4/20 0.55
PDGFRA P16234 4/20 0.55
NPC1 O15118 2/20 0.54
RAB9A P51151 2/20 0.54
MEN1 O00255 1/20 0.54
KMT2A Q03164 1/20 0.54
MAPK13 O15264 1/20 0.53
MAPK12 P53778 1/20 0.53
MAPK11 Q15759 1/20 0.53
MAPK14 Q16539 1/20 0.53
JAK3 P52333 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5470852 0.90 ADORA1 (0.69) JAK2ADORA1CAMK2DABL1PDGFRB
SCHEMBL5472823 0.86 ADORA1 (0.57) JAK2ADORA1CAMK2DABL1PDGFRB
SCHEMBL5472470 0.86 ADORA3 (0.65) JAK2ADORA1CAMK2DABL1PDGFRB
SCHEMBL5472892 0.86 JAK2 (0.76) CYP2C19JAK2ADORA1CAMK2DMEN1
SCHEMBL5472976 0.86 PIK3CA (0.59) JAK2ADORA1CAMK2DNPC1RAB9A
SCHEMBL26884030 0.85 TLR7 (0.54) DYRK1ACYP1A2CYP3A4CYP2C19JAK2
SCHEMBL5469085 0.83 ABL1 (0.57) JAK2ADORA1CAMK2DABL1PDGFRB
SCHEMBL5465350 0.83 SIRT2 (0.68) DYRK1AJAK2ADORA1CAMK2DABL1
SCHEMBL5470733 0.82 MEN1 (0.56) CYP2C19JAK2ADORA1CAMK2DABL1
SCHEMBL5462749 0.80 SCN10A (0.54) JAK2ADORA1CAMK2DABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070099938-A1 Antistress drug and medical use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2007-05-03 US disclosed
EP-1679309-A1 ANTISTRESS DRUG AND MEDICAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2006-07-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070099938-A1 Antistress drug and medical use thereof NPSR1, MC2R, SRR DYRK1A 600/4885CYP1A2 500/4885CYP3A4 386/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.